or Try an Advanced Search...

    ETF Components for PSIL - AdvisorShares Psychedelics ETF


    Below is a list of stocks held by this ETF. We only list holdings in the same market. If this is a global ETF, there may be additional components other than those listed here.

    Holdings

    Symbol Grade Price % Change Allocation
    MNMD B 5.04 16.26
    CYBN F 0.00 8.98
    CMPS D 3.39 6.91
    ATAI C -3.76 6.05
    GHRS B 4.38 5.26
    ITCI C -2.19 4.97
    ALKS F 0.80 4.48
    RLMD F -1.08 4.07
    SAGE F 6.37 2.89

    Represented by ETF Holdings

    Keywords: Biopharmaceutical Drugs Entheogens Major Depressive Disorder Mental Health Neurochemistry Psychoactive Drugs Biotechnology Depressive Disorder Drug Development Hyperactivity Disorder N Dimethyltryptamine Neuroscience Psychedelic Drug Psychiatric And Neurological Disorders Psychiatry Schizophrenia Treatment Resistant Depression Adjunctive Therapy Aging Associated Diseases
    Industries: Biotechnology Drug Manufacturers - Specialty & Generic Medical Care Facilities

    Recent News for AdvisorShares Psychedelics ETF & its Holdings

    Date Stock Title
    May 4 MNMD MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York
    May 3 CMPS Compass Pathways to announce first quarter financial results on May 8, 2024
    May 2 ALKS Alkermes' (ALKS) Q1 Earnings & Revenues Fall Shy of Estimates
    May 2 ALKS Alkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk
    May 2 MNMD MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
    May 2 CMPS Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment
    May 1 ALKS Alkermes plc (ALKS) Q1 2024 Earnings Call Transcript
    May 1 ALKS Alkermes plc 2024 Q1 - Results - Earnings Call Presentation
    May 1 ITCI Acadia Pharmaceuticals (ACAD) Earnings Expected to Grow: Should You Buy?
    May 1 ALKS Alkermes (ALKS) Reports Q1 Earnings: What Key Metrics Have to Say
    May 1 ALKS Alkermes (ALKS) Q1 Earnings and Revenues Miss Estimates
    May 1 ALKS Alkermes Non-GAAP EPS of $0.43 misses by $0.15, revenue of $350.4M misses by $9.87M
    May 1 ALKS Alkermes plc Reports First Quarter 2024 Financial Results
    Apr 30 SAGE Sage Therapeutics, Inc. (NASDAQ:SAGE) Q1 2024 Earnings Call Transcript
    Apr 30 ALKS Alkermes Q1 2024 Earnings Preview
    Apr 30 ALKS How To Trade Biotech Stocks: Can These Three Tips Help You Make More Profits?
    Apr 30 ITCI Intra-Cellular Therapies to Host First Quarter 2024 Financial Results Conference Call and Webcast
    Apr 30 ITCI Intra-Cellular Therapies: Positive MDD Data And Commercial Momentum Make It A Buy
    Apr 29 CMPS Psychedelic drug developers could benefit from NIH funding for chronic pain
    Apr 29 MNMD Psychedelic drug developers could benefit from NIH funding for chronic pain
    AdvisorShares Trust - AdvisorShares Psychedelics ETF is an exchange traded fund launched and managed by AdvisorShares Investments, LLC. The fund invests in public equity markets of global region. It invests directly and through derivatives in stocks of companies operating across healthcare, pharmaceuticals, biotechnology and life sciences companies focused on plant-based psychedelic medicines as well as other companies with business activities in the psychedelics industry sectors. The fund uses derivatives such as swaps to create its portfolio. It invests in growth and value stocks of companies across diversified market capitalization. The investment seeks long-term capital appreciation. AdvisorShares Trust - AdvisorShares Psychedelics ETF is domiciled in the United States.
    Exchange Traded Funds Biotechnology Pharmaceutical Advisorshares
    Back to the Main PSIL Page...